title: Haemophilus influenzae meningitis in Manitoba and the Keewatin District, NWT: potential for mass vaccination.
abstract: A community-based surveillance study of all central nervous system infections was carried out in Manitoba and the Keewatin District, NWT, between Apr. 1, 1981, and Mar. 31, 1984. There were 201 cases of bacterial meningitis in Manitoba over the study period, 81 (40%) caused by Haemophilus influenzae; all but one isolate tested were type b (Hib). There were nine cases of H. influenzae meningitis in the Keewatin District. The overall annual incidence rate of H. influenzae meningitis in Manitoba was 2.5/100,000; for children under 5 years the rate was 32.1/100,000. For the Keewatin District the corresponding rates were 69.6/100,000 and 530/100,000. A total of 85% and 100% of the cases of H. influenzae meningitis occurred by 24 months of age in Manitoba and the Keewatin District respectively. The age at onset was earlier in native Indian children (22 cases) and Inuit children (9 cases) than in non-native children (59 cases) (p less than 0.005); thus, vaccine prevention of Hib meningitis will likely be more difficult in native Indian and Métis children. Without evaluating the increased potential of H. influenzae vaccines to prevent nonmeningitic forms of disease, we concluded that mass childhood vaccination with polyribosylribitolphosphate (PRP) vaccine is not warranted in Manitoba or the Keewatin District. Immunogenicity studies suggest that administration of conjugated Hib vaccines such as PRP-D in infancy may prevent approximately one-third to two-thirds of cases of H. influenzae meningitis; these vaccines warrant consideration for use in mass childhood vaccination programs.
authors.affiliation: Department of Community and Northern Medicine, University of Manitoba, Winnipeg.
authors.forename: G W
authors.initials: GW
authors.lastname: Hammond
authors.forename: B E
authors.initials: BE
authors.lastname: Rutherford
authors.forename: R
authors.initials: R
authors.lastname: Malazdrewicz
authors.forename: N
authors.initials: N
authors.lastname: MacFarlane
authors.forename: N
authors.initials: N
authors.lastname: Pillay
authors.forename: R B
authors.initials: RB
authors.lastname: Tate
authors.forename: L E
authors.initials: LE
authors.lastname: Nicolle
authors.forename: B D
authors.initials: BD
authors.lastname: Postl
authors.forename: H G
authors.initials: HG
authors.lastname: Stiver
mesh_terms: D000367:Age Factors; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*; D002170:Canada; D002675:Child, Preschool; D004168:Diphtheria Toxoid / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D006193:Haemophilus influenzae / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007198:Indians, North American; D007223:Infant; D004930:Inuit; D008350:Manitoba; D008583:Meningitis, Haemophilus / Q000453:epidemiology / Q000208:ethnology / Q000517:prevention & control*; D010428:Pentosephosphates / Q000627:therapeutic use; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use; D014611:Vaccination; D044465:White People
chemical_list: D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D010428:Pentosephosphates; D011135:Polysaccharides, Bacterial; C003191:polyribose phosphate